BioSpace News Archive

Gino Van Heeke, PhD, is the chief scientific officer of LabGenius Therapeutics. He has over 30 years of experience in biologics and small molecule drug discovery and development. He has held leadership roles in both biotech and large pharmaceutical companies, including chief scientific officer at Engitix Ltd and senior director of discovery and early development at Ablynx. Prior to that, he held various senior positions at Novartis, culminating in his role as executive director of biologics.

In this episode presented by DIA, BioSpace’s head of insights Lori Ellis discusses the underrepresentation of women in clinical trials with Martin Hodosi, partner at Kearney and Melissa Laitner, director of strategic initiatives at the National Academy of Medicine.

Experts express concern that last week’s unprecedented FDA layoffs will trigger a little-known mechanism that could result in a “disaster” the Trump administration doesn’t see coming.

Jefferies analysts predict Annexon’s tanruprubart could be approved by mid-2026.

Known as the home of big-name companies including Johnson & Johnson, New Jersey has become a destination for more and more small and midsize life sciences businesses. Choose New Jersey, Grace Therapeutics and Onyx Equities executives discuss the state’s life sciences scene.

The Fourth Circuit’s ruling follows a Supreme Court verdict that also allowed the Trump administration to move forward with its mass layoffs at federal agencies.

Leerink analysts noted, however, that Uplizna’s slow onset of therapeutic efficacy compares unfavorably to would-be competitors in generalized myasthenia gravis.

Pharma stocks went on a wild ride Wednesday amid whiplashing tariff threats from the U.S. president.

Biotech companies are already seeing regulatory delays and plenty of uncertainty after around 3,500 FDA employees were cut by the Trump administration.

According to Tempest, its options include a partnership or licensing deal, as well as a merger or an acquisition.